Fatty acid biosynthesis as a target for novel antibacterials

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• The bacterial fatty acid synthesis (FAS) pathway is a validated target for novel antibacterial development.
• Extensive research in *Escherichia coli* provides a foundation, including known crystal structures and identified homologous genes in pathogens.
• Existing drugs like triclosan and isoniazid, along with experimental compounds such as thiolactomycin and cerulenin, target specific steps in the FAS pathway.

Purpose of the Study:

• To review current inhibitors of the bacterial fatty acid synthesis pathway.
• To explore potential future development strategies for novel antibacterial agents targeting this pathway.

Main Methods:

• Literature review of existing antibacterial compounds targeting fatty acid synthesis.
• Analysis of the bacterial fatty acid synthesis pathway in *Escherichia coli* and other pathogens.
• Identification of potential new targets and inhibitors within the pathway.

Main Results:

• Several compounds, including triclosan, isoniazid, thiolactomycin, and cerulenin, are established inhibitors of the bacterial FAS pathway.
• Homologous genes for the FAS pathway are conserved across important bacterial pathogens.
• Structural information for key enzymes in the pathway is available.

Conclusions:

• The bacterial fatty acid synthesis pathway remains a highly promising target for the development of new antibacterial drugs.
• Further exploration of inhibitors and pathway enzymes could lead to effective novel antibiotics.
• Leveraging existing knowledge and structural data can accelerate the discovery of new antibacterial agents.